Boston, US – At the CAR-TCR Summit Series, Venera Kuci Emruli from Strike Pharma participated in scientific discussions highlighting the rapid progress and evolving landscape within CAR-T and TCR-based therapies.

Key topics addressed throughout the meeting included the growing potential of in-vivo CAR-T approaches, continued expansion of CAR-T therapies beyond oncology indications, and the importance of collaboration across industry and academia to accelerate development and improve patient access. Discussions also focused on advances in manufacturing technologies aimed at reducing production timelines and costs, the role of robust analytical methods in process development and quality assurance, and the potential benefits of introducing CAR-T therapies earlier in treatment pathways. In addition, patient advocacy and patient-centred perspectives were highlighted as important drivers in the continued advancement and accessibility of cell therapies.

About Strike Pharma (www.strikepharma.com)

Headquartered in Uppsala, Sweden, Strike Pharma is using the company’s proprietary Adaptable Drug Affinity Conjugate (ADAC) technology to take precision medicine to a new level, enabling development of truly individualized immunotherapeutic treatments based on the genetic profile of each patient’s tumor. Such highly targeted treatment offers the potential to not only increase therapeutic efficacy, but also to reduce dosage levels thereby minimizing the risk of side effects.

Today, Strike Pharma’s development program is focused on selection of novel, clinically-relevant candidates for use as cancer immunotherapeutic treatments. However, the company is confident that the ADAC technology platform has the potential to facilitate development of many other antibody-based therapeutics and that this novel approach will have a significant impact across a wide variety of disease indications within the rapidly developing field of personalized medicine.

Strike Pharma was founded in 2020 with the aim of commercializing ADAC technology. Investors include Eir Ventures, Flerie Invest, Uppsala University Invest, Almi Invest, SLU Invest and Monesi Förvaltnings.

Enquiries

Mårten Winge CEO

+46 (0) 70 657 59 27

[email protected]